Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia March 6, 2023
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer March 6, 2023
TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery March 1, 2023
Capital Rx Ranks in the Top 50 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies for the Second Year in a Row February 28, 2023
Third Annual Science2Startup (S2S)™ Symposium on May 3, 2023 Will Foster Collaboration Between Researchers, Entrepreneurs and Top Investors February 28, 2023
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden February 27, 2023
Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration February 27, 2023
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy February 27, 2023